-
Mashup Score: 5
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited. Methods A multicentre observational study evaluated the immunogenicity and safety of the two-dose regimen BNT162b2 mRNA vaccine in adult patients with AIIRD (n=686)…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3
In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. These data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In our June issue - ICYMI: #Safety and #immunogenicity of one versus two doses of the #COVID19 #vaccine BNT162b2 for patients with #cancer: interim analysis of a prospective observational study https://t.co/bMQfOPrZS0
-
-
Mashup Score: 1
Objective To investigate the efficacy, safety, immunogenicity and pharmacokinetics of biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced reference ADL (ADL-EU) in patients with active rheumatoid arthritis (RA) on longer-term treatment and after being switched from ADL-EU to ADL-PF. Methods In this multinational, double-blind study, patients with active RA were…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet-
❓Interested in #adalimumab #biosimilars in #RA: ▶️#biosimilar PF-06410293 showed comparable #efficacy, #safety and #immunogenicity compared to reference adalimumab up to week 52 ▶️unaffected by a blinded treatment switch at week 26 🔗https://t.co/AETDvsrdM7 https://t.co/BDtIYkkYHB
-
-
Mashup Score: 0
In patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. These data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW Research: #Safety and #immunogenicity of one versus two doses of the #COVID19 #vaccine BNT162b2 for patients with #cancer: interim analysis of a prospective observational study https://t.co/bMQfOPJBgA
-
-
Mashup Score: 0
The phase 2b-3 trial analyzing the efficacy of the ALVAC–gp120 regimen showed that it did not prevent an HIV-1 infection among the participants in the study at 24 months.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
“Despite promising #immunogenicity, this canarypox–protein #HIV vaccine regimen was not efficacious in preventing the acquisition of HIV-1 #infection in our trial population in South Africa.” https://t.co/7Vtdz2c7xn
-
-
Mashup Score: 3Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion - 3 year(s) ago
Immune checkpoint inhibition does not benefit all patients. This Review discusses how antigen presentation, which is crucial for the success of this therapy, may be disrupted in tumours and dendritic cells of patients, and how tumours may further evade natural killer cell recognition.
Source: Nature Reviews CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @AuclairDan: #Antigen presentation in #cancer: insights into tumour #immunogenicity and immune evasion https://t.co/kXADdnSJAc)
-
-
Mashup Score: 1Learning the language of sugars - 4 year(s) ago
Deep learning and bioinformatics tools enable in-depth study of glycan molecules for understanding infections and disease
Source: Wyss InstituteCategories: Healthcare Professionals, Latest HeadlinesTweet-
Learning the language of sugars @wyssinstitute https://t.co/ZROCxRYu3k #glycan #SugarBase #SweetTalk #SweetOrigins #InfectiousDisease #immunogenicity #pathogen https://t.co/Kb26zeWRlM
-
-
Mashup Score: 1
The rBCG-N-hRSV vaccine had a good safety profile and induced specific cellular and humoral responses.
Source: EClinicalMedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Research Article: Safety and #immunogenicity evaluation of recombinant #BCG #vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial #openaccess #Clinicaltrial https://t.co/a7p7la1uZI
-
-
Mashup Score: 0
A phase 3 Clostridioides difficile (formerly Clostridium) toxoid vaccine was stopped, as the vaccine did not prevent C. difficile infection.
Source: Infectious Disease AdvisorCategories: Infectious Disease, Latest HeadlinesTweet-
The efficacy, #immunogenicity, and safety of a Clostridioides difficile toxoid #vaccine candidate was assessed. https://t.co/LdMuBCnrad
-
-
Mashup Score: 0
A phase 1 study evaluating the safety and immunogenicity of the vaccine candidate mRNA-1273 (Moderna) against COVID-19 showed that the vaccine elicited a strong immune response in older adults.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
A phase 1 study evaluating the safety and #immunogenicity of the #vaccine candidate #mRNA-1273 against #COVID-19 showed that the vaccine elicited a strong #immuneresponse in older #adults. Read More: https://t.co/X5XNqZjlcq
-
Further insights into #immunogenicity after BNTb262 vaccination in people with autoimmune inflammatory #rheumatic diseases: - Most disease-modifying antirheumatic drugs can be continued. - Consider postponing treatment with rituximab when feasible https://t.co/rAqSQieZZ1